药物治疗治疗认知障碍引起的阻塞性睡眠呼吸暂停的概述
Daqiang He1, Jian Chen2, Xiaoxue Du3
1Department of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Frontiers in cellular neuroscience
|September 21, 2023
概括
阻塞性睡眠呼吸暂停 (OSA) 通过睡眠碎片化和间歇性缺氧引起认知障碍. 新型化合物和草药显示出治疗这种OSA并发症的潜力,因为目前的治疗方法不足.
科学领域:
- 神经科学与睡眠医学
- 分子生物学和病理学 分子生物学和病理学
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是一种严重的睡眠障碍,其特点是间歇性缺氧 (IH) 和睡眠碎片化 (SF).
- 认知障碍是OSA的普遍和显著并发症,影响患者的生活质量.
- 如口腔器械和CPAP等现有的治疗方法不足以完全恢复OSA患者的认知功能.
研究的目的:
- 阐明阻塞性睡眠呼吸暂停中潜在的认知功能障碍的分子机制.
- 为了确定潜在的新型治疗目标和治疗OSA相关的认知障碍.
主要方法:
- 在OSA中认知障碍的临床表现的审查.
- 概述了OSA的病理生理学分子机制.
- 对用于认知功能的新型化合物和草药的临床前数据的评估.
主要成果:
- 在OSA中,睡眠碎片化 (SF) 和间歇性缺氧 (IH) 通过包括氧化应激,炎症和亡在内的途径诱导认知障碍.
- 目前用于治疗与OSA相关的认知缺陷的药物治疗方法的疗效有限.
- 临床前研究表明,某些新型化合物和草药具有潜在的治疗益处.
结论:
- 了解OSA引起的认知障碍的分子基础对于开发有效的治疗方法至关重要.
- 迫切需要超越当前临床方法的新型治疗策略.
- 试验性化合物和草药需要进一步研究它们在治疗睡眠障碍的认知功能障碍方面的潜力.
相关概念视频
Sleep Apnea
177
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
177
Management of Insomnia
274
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
274
Sedatives and Hypnotics Drugs: Miscellaneous Agents
196
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
196
CNS Depressants: Barbiturates and Benzodiazepines
303
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
303
Sedatives and Hypnotics: Overview
428
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
428
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


